The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
A comprehensive single-cell atlas of AML uncovers regulatory networks and age-dependent molecular differences to advance the understanding of disease mechanisms and enable subtype-specific therapeutic ...
Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
In the Union Budget, custom duty on 17 cancer therapies have been slashed. But, high-cost therapies are still out of reach ...
In the Union Budget, custom duty on 17 cancer therapies have been slashed. But, high-cost therapies are still out of reach for many.
Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients In this study, we retrospectively classified patients ...
Sellas Life Sciences faces a high bar with its Phase 3 REGAL trial for GPS in AML second remission. REGAL’s ambitious hazard ratio target, open-label design, and heterogeneous control arm raise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results